Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Gain Therapeutics (GANX) Profit After Tax (2020 - 2025)

Gain Therapeutics has reported Profit After Tax over the past 6 years, most recently at -$4.5 million for Q4 2025.

  • Quarterly results put Profit After Tax at -$4.5 million for Q4 2025, down 20.42% from a year ago — trailing twelve months through Dec 2025 was -$20.2 million (up 1.23% YoY), and the annual figure for FY2025 was -$20.2 million, up 1.23%.
  • Profit After Tax for Q4 2025 was -$4.5 million at Gain Therapeutics, up from -$5.3 million in the prior quarter.
  • Over the last five years, Profit After Tax for GANX hit a ceiling of -$2.5 million in Q1 2021 and a floor of -$8.1 million in Q2 2024.
  • Median Profit After Tax over the past 5 years was -$4.6 million (2021), compared with a mean of -$4.7 million.
  • Biggest five-year swings in Profit After Tax: plummeted 554.57% in 2021 and later rose 28.66% in 2025.
  • Gain Therapeutics' Profit After Tax stood at -$3.2 million in 2021, then plummeted by 45.17% to -$4.7 million in 2022, then fell by 1.06% to -$4.7 million in 2023, then grew by 20.23% to -$3.8 million in 2024, then decreased by 20.42% to -$4.5 million in 2025.
  • The last three reported values for Profit After Tax were -$4.5 million (Q4 2025), -$5.3 million (Q3 2025), and -$5.8 million (Q2 2025) per Business Quant data.